| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725581 | Enfermedad Inflamatoria Intestinal al Día | 2017 | 8 Pages |
Abstract
IBD treatment has been the focus of numerous clinical trials, which have consolidated infliximab (suggesting levels in week 2), adalimumab, and golimumab as front-line treatment. The use of ustekinumab in CD is supported, with methotrexate being left as a last resort, except in the case of arthropathy. Other treatments investigated that are worth mentioning were stem cells, other biosimilar, and new drugs.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
G. Trejo, A. Marco-Marqués, S.V. Hernández, M.M. Boscá-Watts,